Ice Cream Plant: FDA finds serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation - and Listeria monocytogenes too - marlerblog.com
Ice Cream Plant: FDA finds serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation - and Listeria monocytogenes too - marlerblog.com — good manufacturing practice, FDA update affecting Pharmaceutical Manufacturing (FDA/DEA).
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 4, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)) should confirm how it applies to their specific situation before acting. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Ice Cream Plant: FDA finds serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation - and Listeria monocytogenes too - marlerblog.com
Who it affects
Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B))
What you must do
Read the update and assess whether your current setup needs to change.
Deadline
No fixed deadline was published, but changes like this are often enforced quickly — act promptly.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- New FDA chief will face COVID woes and calls for drug-approval reform - nature.com
- Pharmaceutical Companies Push Back On ‘Bad Drug’ TV Ads In Tennessee - wpln.org
- Lilly announces $3 billion expansion to injectable drug manufacturing facility for GLP-1 injectables - bioprocessintl.com
- AstraZeneca Completes License Agreement with Dizal for Lung Cancer Treatment Zegfrovy - Contract Pharma
- An interview with John Skerritt, Head of Australia’s TGA - fda.gov